Related Experiment Video
Updated: Dec 20, 2025

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
Published on: June 18, 2020
Myelofibrosis and Portal Hypertension: The Case for Primary Variceal Screening
Marc Samuel Sherman1, Wesley R Samore2, Daniel Stephan Pratt1
1Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
Abstract:
Myelofibrosis is a hematologic condition that predisposes to the formation of large and small portal venous clots. Portal injury is believed to underlie the mechanism of development of noncirrhotic portal hypertension in this population. We describe a patient with myelofibrosis, proven portal hypertension, and extramedullary hematopoiesis with no imaging or pathologic evidence of microvascular or macrovascular portal clot. We provide a concise review of the literature which highlights that patients with myelofibrosis and related conditions of polycythemia vera and essential thrombocytosis present not infrequently with portal hypertension and variceal bleeding. We propose this population may benefit from primary variceal screening.
Insights
Myelofibrosis can cause portal hypertension and bleeding, even without clots. Patients with myelofibrosis may benefit from regular screening for esophageal varices.
Area of Science:
- Hematology
- Gastroenterology
- Vascular Medicine
Background:
- Myelofibrosis is a myeloproliferative neoplasm associated with bone marrow fibrosis.
- Portal venous clots are a known complication, potentially leading to noncirrhotic portal hypertension.
- Extramedullary hematopoiesis is common in myelofibrosis.
Observation:
- A case of myelofibrosis with portal hypertension and extramedullary hematopoiesis is presented.
- This patient lacked imaging or pathological evidence of portal venous clots (microvascular or macrovascular).
Findings:
- Literature review indicates a significant incidence of portal hypertension and variceal bleeding in myelofibrosis, polycythemia vera, and essential thrombocytosis.
- Portal hypertension in myelofibrosis may occur independently of identifiable portal venous thrombosis.
Implications:
- Patients with myelofibrosis and related disorders are at risk for portal hypertension and its complications.
- Primary screening for esophageal varices is proposed for this patient population.
- Further research into the mechanisms of noncirrhotic portal hypertension in myelofibrosis is warranted.
More Related Videos
Related Concept Videos
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Esophageal Varices-I: Introduction
Hepatic Portal System
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Varicose Veins II: Diagnostic Studies and Interprofessional Care

